Franklin Resources Inc. Has $1.81 Million Stock Position in COMPASS Pathways plc (NASDAQ:CMPS)

Franklin Resources Inc. boosted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 4.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 295,785 shares of the company’s stock after buying an additional 12,599 shares during the period. Franklin Resources Inc.’s holdings in COMPASS Pathways were worth $1,810,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Green Alpha Advisors LLC acquired a new stake in shares of COMPASS Pathways during the third quarter valued at approximately $99,000. Y Intercept Hong Kong Ltd acquired a new stake in COMPASS Pathways during the 3rd quarter valued at $131,000. Fore Capital LLC purchased a new stake in shares of COMPASS Pathways in the second quarter valued at $181,000. Geode Capital Management LLC boosted its position in shares of COMPASS Pathways by 160.3% in the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock worth $266,000 after buying an additional 25,970 shares during the period. Finally, AdvisorShares Investments LLC grew its holdings in shares of COMPASS Pathways by 13.5% during the second quarter. AdvisorShares Investments LLC now owns 60,882 shares of the company’s stock valued at $362,000 after buying an additional 7,243 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $4.14 on Friday. The firm has a market cap of $283.26 million, a price-to-earnings ratio of -1.88 and a beta of 2.25. The company’s fifty day moving average is $4.86 and its 200-day moving average is $6.13. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a 12 month low of $3.86 and a 12 month high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the company earned ($0.67) EPS. Equities analysts expect that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CMPS has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Royal Bank of Canada decreased their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, November 1st. HC Wainwright dropped their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Maxim Group decreased their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways has an average rating of “Buy” and a consensus target price of $33.60.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.